
|Articles|April 27, 2012
AstraZeneca C.E.O. to Step Down
Advertisement
David Brennan, the chief executive of AstraZeneca, will step down on June 1 as the big British pharmaceutical company struggles with competition from makers of generic drugs and the failure of several drug development projects.
Mr. Brennan, 58, who has been in his post for six years, was under some pressure from shareholders to resign because of AstraZeneca’s performance.
Read the full story:
Source: The New York Times
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
CDC Reduces US Childhood Immunization Schedule From 17 to 11 Diseases
2
GLP-1s More Effective at Preventing Colorectal Cancer Than Aspirin
3
Telemedicine Utilization and Preventive Services Among a Rural Population
4
Nimbus Therapeutics, Eli Lilly Partner to Develop Novel Oral Metabolic Drug
5





























































